Dr. Axe Wire · Study decoded · gut

Preterm Infant Gut Bacteria Mix Linked To Brain White Matter Development

A probiotic-prebiotic blend reshaped gut bacteria in premature infants, and the same bacterial shifts tracked with brain white matter development.

By Dr. Axe Editorial Team · October 20, 2026 · 1 source · Understand

A randomized trial published October 7, 2026, in Gut Microbes found that a daily probiotic-prebiotic blend shifted premature infants' gut bacteria toward communities whose activity was linked to better brain white matter development.

84infants studied

99randomized, 2018-2022

The trial randomized 99 infants born at 24 to 30 weeks of gestation to a daily supplement or placebo from 48 to 72 hours after birth to 36 weeks postmenstrual age. The supplement combined Bifidobacterium breve M-16V (3 billion colony-forming units daily at full feeding), prebiotic fiber and L-glutamine. The strain was picked for its record of safe use in neonatal intensive care for premature and low-birth-weight babies. Stool from 84 infants was sequenced; 76 had brain MRI at term-equivalent age.

By week one, the strain was detected in 97.3% of supplemented infants versus 9.1% on placebo, and Bifidobacterium stayed higher through week six. At three weeks old, infants who later showed delayed white matter myelination had less capacity in two pyruvate-fermentation pathways than infants with normal myelination; both pathways were higher in the supplemented group.

Pyruvate fermentation is how certain gut bacteria make acetate and lactate, byproducts cells can use for energy when oxygen is scarce, as it often is in preterm tissue. Citing earlier studies, the authors note that lactate has supported brain cell growth and protection in mice, and say the link between these pathways and brain development suggests a possible gut-brain mechanism needing further study.

Probiotic strain detected at week 1: supplement vs placebo

Gut Microbes, 2026, Voulgari-Kokota et al.

Overall brain injury scores did not differ between groups; the bacteria-brain pattern came from a secondary, after-the-fact analysis, not a direct treatment comparison. The trial was sized for a different endpoint, ran at one NICU, and some placebo infants picked up the probiotic strain, which may have blunted group differences. The study was co-financed by a supplement maker that employs five of the authors; the authors say those employees did not take part in the microbiome or MRI analysis.

Dr. Axe’s Take

This trial shows a targeted probiotic strain paired with prebiotic fiber and glutamine reliably pushes a preterm infant's gut bacteria toward the Bifidobacterium-dominant pattern seen in healthy term infants, and does it fast. The brain connection is still an association from a secondary look at the data, not proof the supplement changed anyone's brain outcome. If your baby is in the NICU, I'd ask the neonatology team whether a Bifidobacterium breve feeding protocol is part of their unit's practice; this strain has a safety track record there. This is hospital-supervised nutrition, not a home supplementation decision.

— Dr. Axe

Take the Gut Health Quiz →

Study summary

Who: 99 infants born at 24-30 weeks gestation, randomized; 84 with usable microbiome data, 76 with brain MRI at term-equivalent age
Design: Double-blind, randomized, placebo-controlled, single-center secondary analysis; enrolled 2018-2022
Dose: Bifidobacterium breve M-16V up to 3 billion CFU/day, prebiotic fiber blend and L-glutamine, from 48-72 hours after birth to 36 weeks postmenstrual age
Primary result: Probiotic strain detected in 97.3% of supplemented infants vs 9.1% of placebo infants at week 1; Bifidobacterium abundance higher through week 6
Secondary: Two pyruvate-fermentation pathways lower in infants with delayed white matter myelination (log2 change 1.34 and 1.47); no significant difference in overall brain injury scores between randomized groups
Funding / conflicts: Funded by the Athena Grant (Utrecht Center for Food and Health), a subsidy from the Dutch Ministry of Economic Affairs, Utrecht Province and the municipality of Utrecht, with co-financing from a supplement maker. Conflicts declared in the PubMed record: five authors are employees of that supplement maker; the authors state they were not involved in the microbiome or MRI analysis. The other authors declare no competing interests.
Date: Oct 7, 2026